NICE has released an adoption resource, which aims to support people using the NICE guidance - Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. This resource has been designed for both clinical and non-clinical staff who are planning to adopt the technologies recommended in the guidance. It will be particularly relevant and useful to BSG members who provide and/or commission gastroenterology services. It supports the use of faecal calprotectin testing as an option to help doctors distinguish between inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome.

The resource includes real-life examples from organisations that have adopted and used faecal calprotectin testing within their primary care pathways. Clinicians who participated in the development of the resource, reported that benefits of adopting the recommended technologies can include:

  • Improved clinical management of patients who present with lower gastrointestinal symptoms
  • Greater reassurance and clinical confidence in reaching an accurate diagnosis
  • Reduced anxiety for patients